NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers
- PMID: 8703299
- DOI: 10.1016/0893-133X(95)00137-3
NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers
Abstract
A rapidly growing body of preclinical data has implicated the glutamatergic N-methyl-d-aspartate (NMDA) receptor in memory and other cognitive processes. There is comparatively less information about this receptor system in human cognition. We examined the effects of subanesthetic doses of ketamine, a noncompetitive NMDA receptor antagonist, on two forms of memory, free recall and recognition, as well as attention and behavior in a double-blind, placebo-controlled, 1-hour infusion in 15 healthy volunteers. Ketamine produced decrements in free recall, recognition memory, and attention. In addition, ketamine induced a brief psychosis in our healthy volunteers marked by thought disorder and withdrawal-retardation. Ketamine-induced memory impairments were not accounted for by changes in subject's attention and were not significantly related to psychosis ratings. These data suggest that the NMDA receptor plays a direct role in two types of explicit memory. The implications of these data for the pathophysiology of schizophrenia are discussed.
Similar articles
-
Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.Neuropsychopharmacology. 1997 Sep;17(3):141-50. doi: 10.1016/S0893-133X(97)00036-5. Neuropsychopharmacology. 1997. PMID: 9272481 Clinical Trial.
-
The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers.Psychopharmacology (Berl). 2005 Dec;183(3):265-74. doi: 10.1007/s00213-005-0177-2. Epub 2005 Oct 12. Psychopharmacology (Berl). 2005. PMID: 16220331 Clinical Trial.
-
Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities?Neuropsychopharmacology. 1998 Nov;19(5):434-44. doi: 10.1016/S0893-133X(98)00030-X. Neuropsychopharmacology. 1998. PMID: 9778665 Clinical Trial.
-
[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].Encephale. 2001 Jan-Feb;27(1):53-9. Encephale. 2001. PMID: 11294039 Review. French.
-
The NMDA antagonist model for schizophrenia: promise and pitfalls.Pharmacopsychiatry. 1998 Jul;31 Suppl 2:104-9. doi: 10.1055/s-2007-979354. Pharmacopsychiatry. 1998. PMID: 9754841 Review.
Cited by
-
NMDA Receptors: Distribution, Role, and Insights into Neuropsychiatric Disorders.Pharmaceuticals (Basel). 2024 Sep 25;17(10):1265. doi: 10.3390/ph17101265. Pharmaceuticals (Basel). 2024. PMID: 39458906 Free PMC article. Review.
-
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments.Proc Natl Acad Sci U S A. 2023 Dec 5;120(49):e2305772120. doi: 10.1073/pnas.2305772120. Epub 2023 Nov 27. Proc Natl Acad Sci U S A. 2023. PMID: 38011560 Free PMC article. Review.
-
Brain NMDA Receptors in Schizophrenia and Depression.Biomolecules. 2020 Jun 23;10(6):947. doi: 10.3390/biom10060947. Biomolecules. 2020. PMID: 32585886 Free PMC article. Review.
-
Stimulus-specific regulation of visual oddball differentiation in posterior parietal cortex.Sci Rep. 2020 Aug 18;10(1):13973. doi: 10.1038/s41598-020-70448-6. Sci Rep. 2020. PMID: 32811878 Free PMC article.
-
Ketamine evoked disruption of entorhinal and hippocampal spatial maps.bioRxiv [Preprint]. 2023 Feb 6:2023.02.05.527227. doi: 10.1101/2023.02.05.527227. bioRxiv. 2023. Update in: Nat Commun. 2023 Oct 7;14(1):6285. doi: 10.1038/s41467-023-41750-4 PMID: 36798242 Free PMC article. Updated. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
